CRP and myeloid sarcoma: Immune marker levels of 1008 healthy controls served as a reference.<h4>Results</h4>AP use was significantly associated with higher plasma levels of beta defensin 2 (BD-2) (<i>β</i> = 0.094, <i>p</i> = 0.8E-4), AD use with higher serum levels of CRP (<i>β</i> = 0.072, <i>p</i> = 0.8E-3), and MS use with higher plasma levels of soluble interleukin 2 receptor (sIL-2R) (<i>β</i> = 0.063, <i>p</i> = 0.9E-4).